GERD 5: Antireflux Surgery, Magnetic Sphincter Augmentation, and Endoscopic Therapies

Episode keywords: Nissen fundoplication GERD, Toupet partial fundoplication, laparoscopic antireflux surgery, LINX magnetic sphincter augmentation, Roux-en-Y gastric bypass GERD, sleeve gastrectomy GERD worsening, transoral incisionless fundoplication TIF, antireflux surgery outcomes, GERD surgery recurrence

Episode Summary

Fundoplication is not just a sphincter tightening. Each surgical step corrects a specific pathophysiologic defect in the antireflux barrier. This episode walks through the four steps of fundoplication and what each one does mechanically, the distinction between full and partial wraps and when each is appropriate, the critical interaction between morbid obesity and surgical choice, the LINX device's specific niche, and the evidence base for endoscopic antireflux therapies including TIF.

Key Topics

• Fundoplication -- four steps and their mechanisms: (1) Creating an intra-abdominal esophageal segment returns the distal esophagus to the positive-pressure abdominal environment, where elevated abdominal pressure squeezes the esophagus shut rather than promoting reflux. (2) Hiatal hernia reduction eliminates the intrathoracic reservoir that re-refluxes its contents. (3) Crural approximation re-establishes skeletal muscle buttressing of the LES. (4) Fundic wrap narrows the angle of His (restoring the flap valve), acts as a one-way mechanical valve, and prevents fundal distention that would otherwise trigger TLESRs. Boards test each of these mechanisms individually.
• Wrap types: Nissen is 360 degrees with the strongest antireflux effect and the most side effects (dysphagia, gas-bloat syndrome, inability to belch or vomit). Toupet is posterior 270 degrees. Dor is anterior 180 degrees. Partial wraps have less antireflux efficacy but fewer obstructive side effects and are preferred when esophageal peristalsis is impaired.
• IEM and wrap selection: If manometry shows ineffective esophageal motility, a Nissen wrap creates a high-pressure zone that weak peristalsis cannot overcome, resulting in post-operative dysphagia. Manometry before fundoplication is standard of care precisely to identify this. Many surgeons choose Toupet in patients with documented IEM.
• Long-term outcomes: Swedish Patient Registry data from 2,655 fundoplication patients showed 17.7% reflux recurrence at mean 5.1 years follow-up. Fundoplication is effective but not permanent. Risk factors for recurrence include female sex, older age, and comorbidity. Patients should understand that long-term PPI use may still be necessary.
• Morbid obesity and surgical choice: In patients with BMI greater than 35, fundoplication has a higher failure rate due to persistent mechanical stress from elevated intra-abdominal pressure and ongoing visceral adiposity effects. Roux-en-Y gastric bypass is the preferred operation for GERD in morbidly obese patients. It addresses both reflux (small gastric pouch, Roux limb diverting bile and pancreatic secretions) and obesity simultaneously. Sleeve gastrectomy converts the stomach to a high-pressure tube, removes the fundus, disrupts the angle of His, and causes or worsens GERD. De novo GERD after sleeve gastrectomy is a recognized complication. If the board presents a morbidly obese patient with significant GERD considering bariatric surgery, the answer is Roux-en-Y, not sleeve.
• LINX magnetic sphincter augmentation: A ring of titanium beads with magnetic cores placed laparoscopically around the distal esophagus. Magnetic attraction maintains closure; swallowing force temporarily separates beads. Preserves ability to belch and vomit in most patients. No randomized comparison to fundoplication exists; uncontrolled studies show comparable results. One randomized trial compared LINX to optimized medical therapy and showed MSA superiority for regurgitation control. ACG recommends MSA as an alternative to fundoplication specifically for regurgitation-predominant patients failing medical therapy. Contraindications include large hiatal hernias and certain MRI requirements (though newer designs are MRI-conditional).
• Endoscopic antireflux therapies: Stretta delivers radiofrequency energy to the LES area; results are mixed and guidelines offer limited endorsement. Transoral incisionless fundoplication (TIF) with the EsophyX device creates a partial fundoplication endoscopically with no abdominal incisions. Randomized trials show TIF efficacy for regurgitation. ACG recommends considering TIF for troublesome regurgitation or heartburn without severe esophagitis (LA-C or D) and without hiatal hernia larger than 2 cm. Anti-reflux mucosectomy (ARMS) uses EMR at the cardia to create submucosal fibrosis that tightens the EGJ; data predominantly from Asian centers; promising but not yet established in US practice.

Board Pearls

High-yield: Fundoplication corrects four separate pathophysiologic defects, not just LES pressure. Know what each surgical step does: intra-abdominal segment, hernia reduction, crural repair, and fundic wrap each target a distinct mechanism.
Board trap: A morbidly obese patient with significant GERD is being evaluated for bariatric surgery. Sleeve gastrectomy can worsen or cause de novo GERD. Roux-en-Y gastric bypass is the correct answer.
High-yield: MSA (LINX) is specifically indicated for regurgitation-predominant GERD not responding to medical therapy, not as a blanket alternative to fundoplication for all GERD.

GERD 4: Acid Suppression -- PPIs, P-CABs, and the Vonoprazan Revolution

Episode keywords: PPI mechanism of action, vonoprazan P-CAB GERD, omeprazole equivalents potency, parietal cell proton pump H+K+ATPase, PPI safety evidence, H2 blocker tachyphylaxis, nocturnal acid breakthrough, CYP2C19 PPI metabolism, Laine vonoprazan trial 2023

Episode Summary

Not all PPIs are equal, and vonoprazan is a different class of drug rather than a stronger PPI. This episode traces acid secretion from parietal cell stimulus to proton pump activation, explains why PPIs require meal timing while vonoprazan does not, quantifies potency differences across PPIs using omeprazole equivalents, and covers the Laine 2023 trial showing vonoprazan's superiority in severe erosive esophagitis. PPI safety associations from observational data are contrasted with the randomized controlled trial evidence, which largely exonerates the class.

Key Topics

• Parietal cell physiology and the final common pathway: Three stimulants activate the proton pump. Gastrin binds CCK-2 receptors and raises intracellular calcium. Histamine binds H2 receptors and raises cAMP. Acetylcholine binds M3 receptors and raises calcium. Both calcium and cAMP trigger fusion of tubulovesicles with the canalicular membrane, exposing active H+/K+-ATPase pumps. H2 blockers interrupt only one of three pathways. PPIs and vonoprazan block the pump directly, downstream of all three stimulants regardless of what is activating the cell.
• H2 receptor antagonists: Available agents are cimetidine, famotidine, and nizatidine. Ranitidine was withdrawn due to NDMA (N-nitrosodimethylamine) nitrosamine contamination. H2 blockers relieve symptoms in 50 to 67% of patients. Healing rates for esophagitis are poor compared to PPIs. Tachyphylaxis limits long-term utility. Best role is mild intermittent GERD or as a bedtime add-on for nocturnal acid breakthrough, though tachyphylaxis also limits that indication over time.
• PPI mechanism and meal timing: PPIs are acid-labile prodrugs requiring enteric coating. After duodenal absorption, they enter the parietal cell canalicular space, get protonated in the acidic environment, and form covalent disulfide bonds with cysteine residues on active proton pumps. Only actively secreting pumps are accessible; tubulovesicle-bound pumps are invisible to PPIs. Taking PPIs 30 to 60 minutes before a meal ensures the drug arrives when the meal is stimulating maximum pump activation. Plasma half-life is approximately 90 minutes. Full steady-state suppression requires 3 to 5 days of dosing as successive pumps are inactivated. PPIs are NOT effective for acute breakthrough symptoms -- this is a board trap.
• CYP2C19 metabolism: Most PPIs are metabolized by CYP2C19. Poor metabolizers achieve higher drug levels and better suppression. Rapid metabolizers may have subtherapeutic levels at standard doses. Rabeprazole is least affected by CYP2C19 polymorphisms due to more non-enzymatic conversion.
• Omeprazole equivalents (potency at standard doses): Setting omeprazole 20 mg as 1.00: lansoprazole 15 mg is 0.90; esomeprazole 20 mg is 1.60; rabeprazole 20 mg is 1.82 (most potent standard PPI); pantoprazole 20 mg is 0.23 (roughly one-quarter the acid suppression of omeprazole 20 mg). Pantoprazole's widespread use reflects formulary economics and IV availability, not pharmacologic superiority.
• Nocturnal acid breakthrough: 70 to 80% of patients on twice-daily PPI still have gastric pH below 4 for more than one hour overnight. Clinical significance is often unclear -- many are asymptomatic and healing well. A bedtime H2 blocker can help short-term but tachyphylaxis limits durability. Intervention is warranted primarily when associated with persistent symptoms or non-healing esophagitis.
• PPI safety -- RCT evidence: Moayyedi et al., Gastroenterology 2019, randomized 17,598 patients to pantoprazole versus placebo over 3 years. No significant differences in fractures, dementia, CKD, cardiovascular events, or pneumonia. Enteric infections were modestly higher (1.4% vs 1.0%, OR 1.33). The vast majority of observational safety signals disappear when patients are properly randomized, reflecting residual confounding in population studies. Hypomagnesemia has the strongest mechanistic basis and is a class effect; monitor magnesium in long-term PPI users with symptoms or risk factors.
• Vonoprazan mechanism: Acid-stable, active drug (not a prodrug). No enteric coating needed. Faster absorption. Binds H+/K+-ATPase through ionic interactions with very high affinity. Critically, binds both active AND inactive pumps -- does not require a secreting pump. Half-life 7 to 9 hours versus 90 minutes for PPIs. Not significantly affected by CYP2C19 polymorphisms. Does not require meal timing. Achieves acid suppression on day 1 rather than days 3 to 5.
• Laine et al., Gastroenterology 2023: 1,024 patients with erosive esophagitis randomized to vonoprazan 20 mg versus lansoprazole 30 mg over 8 weeks. Overall healing: 92.9% vs 84.6% (noninferior and superior). LA-C and D subgroup: 91.7% vs 72.0%, a 19.6 percentage point difference. Vonoprazan also superior for maintenance of healing. Potency context: vonoprazan 10 mg daily approximates omeprazole 60 mg; vonoprazan 20 mg approximates omeprazole 60 mg twice daily.

Board Pearls

Board trap: A patient takes their PPI when they feel heartburn and says it does not work. Correct response -- PPIs are not designed for on-demand dosing. They require 3 to 5 days to reach steady state and must be taken before meals when parietal cells are being stimulated.
High-yield: Vonoprazan's three mechanistic advantages over PPIs are meal-timing independence, CYP2C19 independence, and ability to bind inactive pumps. Each traces directly to its structure as an active drug with a long half-life.
Board trap: Pantoprazole is the most common IV PPI but among the weakest oral PPIs. A patient not responding to pantoprazole orally is not on the most potent available therapy. Switching to rabeprazole or esomeprazole before escalating to twice-daily dosing is a reasonable step.

GERD 3: Acid Pocket, Endoscopy, and the Initial Approach

Episode keywords: acid pocket GERD, LA classification reflux esophagitis, Barrett's esophagus screening ACG AGA, empiric PPI trial, alarm symptoms GERD, non-erosive reflux disease endoscopy, lifestyle modifications GERD, alginates GERD mechanism

Episode Summary

The acid pocket explains why Barrett's esophagus develops specifically at the GEJ rather than randomly throughout the esophagus. This episode covers the postprandial acid pocket and its role in genotoxic injury, the LA classification of reflux esophagitis and which grades actually confirm GERD, why only 30% of heartburn patients have visible esophagitis, the ACG versus AGA Barrett's screening criteria, and the full initial management approach including lifestyle modifications and the pharmacologic options before PPIs.

Key Topics

• The acid pocket: After meals, a layer of newly secreted, unbuffered acid sits on top of gastric contents at the cardia. The Z-line (squamocolumnar junction) is exposed to this acid for more than 10% of the day even in healthy people. In hiatal hernia, the acid pocket migrates above the diaphragm. Dietary nitrate is concentrated in saliva, swallowed, and reduced to nitrite by oral bacteria. When nitrite contacts the acid pocket, it generates nitric oxide and reactive nitrogen species that are genotoxic. The GEJ is therefore simultaneously exposed to acid-peptic injury and nitrosative stress. This dual insult drives intestinal metaplasia at the cardia specifically.
• Three questions endoscopy answers in GERD: Is there reflux esophagitis? Is there a peptic stricture? Is there Barrett's esophagus? Endoscopy does not confirm GERD in a patient with typical symptoms and complete PPI response. That is a clinical diagnosis.
• LA classification: Grade A is mucosal breaks less than 5 mm not extending between fold tops. Grade B is mucosal breaks greater than 5 mm not extending between fold tops. Grade C extends between two or more fold tops but involves less than 75% of circumference. Grade D involves 75% or more of circumference. Grades B through D confirm GERD. Grade A has poor interobserver agreement and can be seen in asymptomatic individuals; it alone does not definitively confirm pathologic reflux.
• The 30% statistic: Only about 30% of patients with frequent heartburn have endoscopic esophagitis. The majority have non-erosive reflux disease. Heartburn severity does not predict esophagitis severity. Symptoms and mucosal damage are poorly correlated.
• Empiric PPI trial: For classic heartburn and regurgitation without alarm symptoms, start an 8-week empiric PPI trial taken 30 to 60 minutes before a meal. Do not scope first. Stop PPIs 2 to 4 weeks before any diagnostic endoscopy; active PPI therapy heals esophagitis and can also mask eosinophilic esophagitis.
• Alarm symptoms requiring endoscopy: Dysphagia, odynophagia, weight loss, GI bleeding, anemia, vomiting. These bypass empiric therapy.
• Barrett's screening -- ACG vs AGA: ACG recommends a single screening EGD for patients with chronic GERD symptoms plus three or more additional risk factors (male sex, age over 50, white race, tobacco use, obesity, family history of Barrett's or esophageal adenocarcinoma). ACG generally does not recommend screening women without multiple risk factors. AGA 2022 considers chronic GERD as one risk factor among many and recommends screening when three or more total risk factors are present, so a white male over 50 with obesity could qualify even without documented GERD symptoms.
• Lifestyle modifications (8 items boards test): Elevate head of bed 6 to 8 inches with blocks (not pillows). Lose weight. Avoid recumbency for 2 to 3 hours after meals. Avoid right-lateral decubitus sleeping (left-lateral keeps the acid pocket below the esophageal inlet). No bedtime snacks. Avoid trigger foods (chocolate, coffee, alcohol, fatty foods). No smoking or alcohol. Avoid medications that reduce LES pressure (calcium channel blockers, nitrates, anticholinergics, theophylline). Evidence for most is limited; weight loss and head-of-bed elevation have the strongest data.
• Other medical options: Alginates form a gel raft on top of gastric contents, physically displacing the acid pocket from the GEJ -- a direct mechanical intervention targeting pathophysiology. Prokinetics (metoclopramide) are no longer recommended; side effect rates approach 30%, including tardive dyskinesia. Baclofen reduces TLESRs but CNS side effects limit clinical utility.

Board Pearls

Board trap: AGA versus ACG Barrett's screening. A 55-year-old white male with obesity and family history of esophageal adenocarcinoma but no GERD symptoms. Under AGA (four risk factors), screening is appropriate. Under ACG, possibly not without chronic GERD.
High-yield: Stop PPIs 2 to 4 weeks before a diagnostic endoscopy. Active PPI therapy heals esophagitis (producing false-negative for erosive disease) and suppresses eosinophilic esophagitis features (producing false-negative for EoE).
Board trap: LA Grade A is not confirmatory for GERD. Only LA-B through D represent objective evidence of pathologic reflux on endoscopy.

GERD 2: The Antireflux Barrier, Clearance, and Hiatal Hernia

Episode keywords: antireflux barrier, hiatal hernia reflux mechanism, esophageal clearance GERD, nocturnal acid reflux, H. pylori Barrett's inverse association, obesity GERD mechanism, IEM reflux esophagitis, angle of His flap valve

Episode Summary

The antireflux barrier has three components, esophageal clearance has four mechanisms, and hiatal hernia disrupts all of them simultaneously. This episode builds on the pathophysiology of Episode 1 to explain why hiatal hernia size correlates with reflux severity, why nighttime reflux is more injurious than daytime reflux, and two systemic factors that modify GERD risk through mechanisms boards specifically test: H. pylori and obesity.

Key Topics

• Three components of the antireflux barrier: The LES smooth muscle provides tonic pressure. The EGJ flap valve (angle of His) creates a geometric one-way valve that tightens when the fundus distends. The crural diaphragm provides skeletal muscle augmentation during inspiration and straining. All three can fail independently or together.
• Hill classification and AFS grading: The flap valve is graded endoscopically. Hill Grade I is a prominent fold closely approximating the scope. Hill Grade IV is no fold at all, a gaping hiatus. AFS Grade 1 indicates all components intact; higher grades indicate progressive failure.
• Four esophageal clearance mechanisms: Gravity, peristalsis, salivation, and submucosal gland bicarbonate secretion. During sleep, three of the four are eliminated simultaneously: the supine position removes gravity, swallowing frequency drops to near zero eliminating peristalsis, and salivation stops. Only submucosal secretion persists. This is why nocturnal reflux is disproportionately injurious.
• IEM and reflux esophagitis: Between 25 and 48% of reflux esophagitis patients have ineffective esophageal motility. IEM impairs clearance and is a risk factor for more severe disease. It is also the primary reason manometry is required before antireflux surgery. A weak esophagus wrapped with a 360-degree Nissen cannot generate sufficient peristaltic force and develops dysphagia.
• Hiatal hernia mechanics: Hernia separates the intrinsic LES from the crural diaphragm, displacing the LES into the negative-pressure thorax. The crura now squeeze around the stomach below the herniated segment, creating a reservoir that readily refluxes. Fundal distention of the herniated segment increases TLESR frequency. The angle of His widens as the hernia enlarges, destroying the flap valve. All three antireflux components fail simultaneously. Hernia size correlates with reflux severity.
• H. pylori and the inverse association: H. pylori causing predominantly corpus (fundic) gastritis leads to parietal cell atrophy and reduced acid production. Less acid means less esophageal injury. This creates an inverse association between H. pylori, Barrett's esophagus, and esophageal adenocarcinoma. Clinical policy: GI societies do NOT recommend routine H. pylori testing and treatment in GERD patients. GERD is NOT a contraindication to treating H. pylori when another indication exists. Do not withhold treatment for peptic ulcer disease because a patient has reflux.
• Obesity and GERD: Dose-dependent positive association with BMI. Visceral adipose tissue increases intragastric pressure, promotes hiatal hernia formation, and secretes adipokines that directly impair esophageal barrier integrity and dilate intercellular spaces. Obesity is also an independent risk factor for Barrett's and esophageal adenocarcinoma beyond its effect on reflux volume.

Board Pearls

Board trap: A patient with GERD has incidentally found H. pylori. Does treating the infection worsen reflux? Treat the H. pylori if an indication exists. Manage GERD on its own merits. Do not withhold treatment.
High-yield: Nocturnal reflux is more injurious because three of four clearance mechanisms are simultaneously absent during sleep. Head-of-bed elevation and avoiding recumbency after meals have direct physiologic rationale from this mechanism.
Board trap: A small hiatal hernia is labeled "clinically insignificant" in a consult note. Incorrect framing. A hiatal hernia simultaneously disrupts LES support, crural augmentation, and flap valve geometry. Its contribution to reflux severity is proportional to its size, not binary.

GERD 1: Pathogenesis — It's Not Just Acid Burns

Episode keywords: GERD pathogenesis, cytokine-mediated esophageal injury, transient LES relaxation TLESR, GABA-B baclofen reflux, LES pressure GERD, nucleus tractus solitarius reflux, ACG GERD definition 2022

Episode Summary

The "acid burn" model of reflux esophagitis has been replaced. This episode covers the Dunbar JAMA 2016 paradigm shift showing that acid triggers a cytokine-mediated inflammatory response that builds from deep to superficial, not from the surface inward. It then establishes the two-component antireflux barrier, the neural control of transient LES relaxations, and one of the most consistently board-tested misconceptions: that most GERD patients have normal resting LES pressure.

Key Topics

• ACG 2022 GERD definition: Reflux of stomach contents causing troublesome symptoms and/or complications, objectively documented by endoscopy or ambulatory pH monitoring. Approximately 20% of Western adults report weekly heartburn.
• The cytokine-mediated injury model: Acid contacts esophageal epithelial cells, which secrete pro-inflammatory cytokines that recruit T lymphocytes. The damage is inflammatory, not chemical. Histologic consequence: basal cell hyperplasia and elongated papillae appear before surface erosions. Injury builds from inside out. This explains why symptom severity does not correlate with endoscopic severity.
• The two-component LES: The intrinsic LES is smooth muscle providing tonic contraction. The extrinsic LES is the crural diaphragm, skeletal muscle that dynamically augments pressure during inspiration and straining. Both components must be understood to explain hiatal hernia and fundoplication mechanics.
• TLESRs as the dominant reflux mechanism: Transient LES relaxations are sudden, prolonged relaxations not triggered by swallowing, lasting more than 10 seconds, representing the normal belch reflex. Controlled by the nucleus tractus solitarius in the medulla. Inhibited by GABA-B neurons, which is why baclofen (a GABA-B agonist) reduces TLESR frequency. CCK-1 receptors mediate intrinsic sphincter relaxation during TLESRs, connecting fatty meals to reflux through a defined pathway.
• The TLESR misconception: GERD patients do not have more TLESRs than normal people. The frequency is the same. What differs is that a higher proportion of TLESRs in GERD are associated with acid reflux rather than just gas venting. The problem is content, not frequency.
• LES pressure in GERD: Most GERD patients have normal resting LES pressure. Only patients with severe erosive esophagitis consistently have abnormally low LES pressure, generally below 10 mmHg. GERD is not simply a "weak sphincter" disease for the majority of patients.

Board Pearls

High-yield: The Dunbar model means histologic changes precede endoscopic findings. Basal cell hyperplasia and T-cell infiltration on biopsy can represent early reflux injury even with a normal-looking mucosal surface.
Board trap: A question states a GERD patient has normal LES pressure and asks if this rules out GERD. It does not. Normal resting LES pressure is the expected finding in most reflux patients.
High-yield: Baclofen reduces TLESRs via GABA-B agonism at the nucleus tractus solitarius. This is a high-frequency board mechanism question.

Motility 7: IEM, Opioid Effects, and Non-Cardiac Chest Pain

Episode keywords: ineffective esophageal motility IEM, scleroderma esophagus manometry, absent contractility, fundoplication IEM, opioid esophageal motility, opioid elevated IRP, non-cardiac chest pain algorithm, functional chest pain neuromodulators, Chicago Classification IEM criteria, visceral hypersensitivity esophagus

Episode Summary

The final episode closes the loop on the normal-IRP side of the Chicago Classification and ties the entire series together. Esophageal hypocontraction — from the scleroderma esophagus to IEM — has a critical intersection with surgical planning: weak peristalsis and a Nissen fundoplication is a mistake that manometry is specifically designed to prevent. The episode also covers opioid-induced esophageal dysfunction (the great mimicker of every motility diagnosis) and the evidence-based stepwise approach to non-cardiac chest pain.

Key Topics

• Scleroderma esophagus: Fibrosis and vascular obliteration damage esophageal smooth muscle. Manometric hypocontraction in ~80% of scleroderma patients. Weak clearance + hypotensive LES = severe GERD with impaired acid clearance. Not scleroderma-specific — identical findings in mixed connective tissue disease, RA, SLE, diabetes, amyloidosis, alcoholism, myxedema, MS, and longstanding GERD. "Scleroderma esophagus" should be reserved for patients with confirmed scleroderma.
• IEM — CCv4.0 criteria:
  • >70% of swallows ineffective (failed: DCI <100, OR weak: DCI 100–450, OR fragmented: peristaltic breaks >5 cm in 20 mmHg isobaric contour with DCI ≥450)
  • OR ≥50% of swallows outright failed (DCI <100)
  • Note: CCv3.0 required ≥50% failed or weak. CCv4.0 made this more stringent.
  • 100% failed peristalsis = Absent contractility — a separate, more severe diagnosis.
• IEM and fundoplication — the critical board intersection:
  • If a patient has IEM and you perform a Nissen (360° wrap), the weakly peristaltic esophagus cannot generate sufficient pressure to push a bolus through the tight wrap → post-operative dysphagia.
  • If IEM is present: use partial fundoplication (Toupet 270° posterior or Dor 180° anterior), or avoid fundoplication altogether.
  • This is the same principle as in achalasia — peristaltic impairment is a contraindication to complete wraps.
• Opioid-induced esophageal dysfunction:
  • Opioids can mimic nearly every HRM diagnosis: elevated IRP (EGJOO, achalasia-like), elevated DCI (hypercontractile), short DL (DES, Type III-like).
  • Opioids are in the explicit EGJOO differential and should be considered in any elevated-IRP pattern.
  • Rule: Before diagnosing ANY primary motility disorder on HRM, check the medication list for opioids. If opioids are present — discontinue (if possible) and repeat the study.
• Non-cardiac chest pain — the stepwise algorithm:
  1. Exclude cardiac, thoracic, and pancreaticobiliary causes first. Cardiology evaluation if needed.
  2. Check for alarm symptoms (dysphagia, weight loss, bleeding) → endoscopy if present.
  3. If no alarm features: check for typical GERD symptoms → endoscopy → pH monitoring if endoscopy normal.
  4. No alarm, no typical GERD symptoms → double-dose PPI trial for 2 months. Relief = GERD confirmed.
  5. PPI failure → esophageal manometry.
  6. Manometry shows motility disorder → treat per disorder-specific guidelines, add neuromodulator.
  7. Normal manometry → functional chest pain. Treat with neuromodulator (TCA, trazodone, SSRI) + cognitive behavioral therapy.
  • Data: Up to 70% of NCCP patients have typical GERD symptoms. Abnormal pH monitoring in 40–60%. ~80% of NCCP patients with abnormal pH or erosive esophagitis achieve pain relief with PPIs. Fewer than 30% have abnormal motility studies.

Board Pearls

High-yield: Manometry before antireflux surgery exists specifically to catch IEM. Nissen + IEM = post-operative dysphagia. Know this cold.

Board trap: Opioid-using patient with HRM showing elevated IRP, premature contractions, and elevated DCI — do not diagnose achalasia + DES + hypercontractile esophagus. The answer is opioid-induced dysmotility.

High-yield: Non-cardiac chest pain algorithm — cardiac exclusion FIRST, then GERD evaluation, then PPI trial, then manometry. Jumping directly to manometry is wrong if the cardiac workup has not been completed.

Motility 6: Distal Esophageal Spasm and Hypercontractile Esophagus

Episode keywords: distal esophageal spasm HRM, corkscrew esophagus, premature contractions DL, nutcracker esophagus vs jackhammer esophagus, hypercontractile esophagus DCI, Chicago Classification DES criteria, Pandolfino 2011 distal latency, contraction front velocity, non-cardiac chest pain motility

Episode Summary

Both DES and hypercontractile esophagus live on the normal-IRP side of the Chicago Classification. Both are rare, both have frustrating treatment responses, and both are full of terminology traps that boards specifically exploit. This episode covers the shift from simultaneous contractions to premature contractions as the defining criterion for DES, the Pandolfino 2011 study that drove that change, and the critical distinction between nutcracker esophagus (amplitude-based, conventional manometry) and hypercontractile/jackhammer esophagus (DCI-based, HRM).

Key Topics

• DES — clinical picture: Episodic dysphagia with chest pain. Barium swallow: corkscrew esophagus (tertiary contractions). Presentation mimics cardiac chest pain.
• The criterion change — simultaneous contractions to premature contractions:
  • Old criterion (conventional manometry): Simultaneous contractions with contraction front velocity >6–9 cm/sec.
  • New criterion (HRM, CCv4.0): Premature contractions with DL <4.5 sec in ≥20% of swallows.
  • Rationale: Pandolfino et al., J Gastroenterol 2011 (n=1,070 HRM studies). Of 91 patients with rapid propagation, 24 had truly short DL — 18 had spastic achalasia, 6 had DES. All 24 had spastic disorders with symptoms. The 67 with rapid CFV but normal DL had heterogeneous findings; only 56% reported dysphagia. Short DL defines a clinically meaningful phenotype. Rapid CFV does not.
  • Contraction front velocity has been dropped from CCv4.0 entirely.
• CCv4.0 DES criteria (all required):
  1. Normal IRP (if elevated → Type III achalasia, not DES)
  2. Premature contractions (DL <4.5 sec) in ≥20% of swallows
  3. Symptoms of dysphagia and/or chest pain
• DES treatment: Variable and inconsistent. Smooth muscle relaxants (CCBs, nitrates, sildenafil, peppermint oil), neuromodulators (TCAs), botulinum toxin, POEM in refractory cases. No reliably effective therapy.
• Nutcracker vs. hypercontractile esophagus — the terminology trap:
  • Nutcracker esophagus (Castell): Distal peristaltic amplitude >2 SD above normal. Amplitude-based. Associated with non-cardiac chest pain and GERD. Clinical importance disputed.
  • Hypercontractile/jackhammer esophagus (CCv3.0, CCv4.0): DCI >8,000 mmHg·cm·sec in ≥20% of swallows. Volume-based (integrates amplitude × duration × length). These are not the same entity.
  • "Nutcracker esophagus" is not a CCv4.0 diagnosis. The term is fading.
• CCv4.0 hypercontractile esophagus criteria (all required):
  1. Normal IRP
  2. DCI >8,000 mmHg·cm·sec in ≥20% of swallows
  3. Symptoms of dysphagia and/or chest pain
  4. Secondary causes excluded (opioids, GERD, EoE)
• Hypercontractile treatment: Mirrors DES. Smooth muscle relaxants, neuromodulators, botulinum toxin, POEM in refractory cases.

Board Pearls

Board trap: HRM shows rapid contraction front velocity with normal DL. Is this DES? No. CCv4.0 requires short DL (<4.5 sec), not rapid CFV. CFV is no longer a diagnostic criterion.

Board trap: Patient with peristaltic amplitude >180 mmHg. Is this hypercontractile esophagus? Not necessarily — you need the DCI, not peak amplitude. Amplitude ≠ DCI.

High-yield: If IRP is elevated and there are premature contractions — that is Type III achalasia, not DES. The IRP is the branch point.

Motility 5: EGJ Outflow Obstruction and FLIP

Episode keywords: EGJ outflow obstruction EGJOO, FLIP panometry, functional luminal imaging probe, EGJ distensibility index, Dallas Consensus FLIP classification, upright IRP, EGJOO differential diagnosis, opioids elevated IRP, timed barium esophagram

Episode Summary

EGJOO is the most over-diagnosed entity in motility. The Chicago Classification v3.0 was too permissive; CCv4.0 significantly tightened the criteria and introduced the concept that manometric EGJOO is always clinically inconclusive without confirmatory testing. This episode covers the full differential, the new criteria, and the FLIP — the tool that tells you what manometry cannot: whether the EGJ actually opens when you push something through it.

Key Topics

• EGJOO pattern: Elevated IRP + preserved peristalsis. Not achalasia (which requires absent peristalsis), but something is obstructing EGJ outflow.
• The differential:
  • Early or evolving achalasia
  • Eosinophilic esophagitis (fibrosis impairing EGJ distensibility)
  • Malignancy at the EGJ
  • Hiatal hernia artifact (especially paraesophageal hernias)
  • Opioid use
  • Obesity (increased intra-abdominal fat)
  • Spurious finding of no clinical importance
• CCv4.0 EGJOO criteria (all required for manometric diagnosis):
  1. Median IRP above ULN in BOTH supine AND upright positions
  2. Some preserved peristalsis
  3. ≥20% of swallows show increased intrabolus pressure
• EGJOO is ALWAYS clinically inconclusive on manometry alone. A clinically relevant diagnosis additionally requires: symptoms of dysphagia and/or chest pain, PLUS confirmatory testing (timed barium esophagram showing delayed emptying, or FLIP showing reduced distensibility).
• Upright IRP pearl: Upright IRP >12 mmHg identifies radiographically confirmed EGJOO with 98% sensitivity. If upright IRP is ≤12 mmHg, true obstruction is unlikely.
• FLIP — functional luminal imaging probe: Impedance planimetry catheter with 16 paired electrodes and a pressure sensor. Measures cross-sectional area using impedance data. Produces a real-time 3D image of the esophagus during balloon distension.
• EGJ Distensibility Index (DI): Narrowest cross-sectional area ÷ intraluminal pressure at that segment. At 60 mL fill volume: 
  • Normal EGJ opening (NEO): DI ≥2.0 mm²/mmHg AND max diameter ≥16 mm
  • Reduced EGJ opening (REO): DI <2.0 mm²/mmHg AND max diameter <12 mm
  • Inconclusive: between NEO and REO
• FLIP panometry contractile responses: Normal = repetitive antegrade contractions (RACs; rule of 6s: ≥6 consecutive antegrade contractions, ≥6 cm axial length, 6±3 per minute). Abnormal: absent, spastic, disordered (pressure >40 mmHg), or diminished (pressure <40 mmHg).
• Dallas Consensus classification grid (EGJ opening × contractile response):
  • NEO + Normal → Normal (major motility disorder highly unlikely)
  • REO + Normal → Mechanical obstruction pattern
  • REO + Spastic → Spastic obstruction (Type III achalasia variant)
  • REO + Absent → Non-spastic obstruction (Types I/II achalasia)
  • NEO + Absent/Diminished → Hypocontractility pattern
  • NEO + Spastic → Possible spasm pattern

Board Pearls

Board trap: Patient on chronic opioids with manometric EGJOO — do not diagnose achalasia. Rule out opioid-induced IRP elevation first.

High-yield: Normal FLIP panometry (NEO + normal contractile response) makes a major motility disorder highly unlikely. Most experts still require HRM to diagnose achalasia, but normal FLIP is strongly reassuring.

Motility 4: Achalasia Treatment — Decision Tree and Landmark Trials

Episode keywords: achalasia treatment, POEM procedure, Heller myotomy, pneumatic dilation achalasia, botulinum toxin achalasia, Boeckxstaens trial NEJM, Werner trial NEJM, Nissen fundoplication achalasia, achalasia GERD after POEM, blown-out myotomy

Episode Summary

Every achalasia treatment has one goal: reduce LES resting pressure so it no longer obstructs ingested material. No treatment restores peristalsis. All are palliative. This episode covers the treatment hierarchy from pharmacotherapy to POEM, the three landmark RCTs that define the evidence base, and the current ACG and ASGE guideline recommendations — including which treatment is preferred for Type III achalasia.

Key Topics

• Three anchoring principles:
  1. All treatments target LES pressure reduction — not esophageal body function.
  2. No treatment restores peristalsis. Lost ganglion cells do not return.
  3. All therapies deteriorate over time. Patients should anticipate retreatment.
• Pharmacotherapy (nitrates/calcium channel blockers): Smooth muscle relaxants taken sublingually 10–30 minutes pre-meal. Side effects common. ACG indicates use only when patient cannot undergo definitive therapy AND has failed botulinum toxin. Last resort, not first line.
• Botulinum toxin injection: Endoscopic injection into LES. Blocks excitatory cholinergic neurons. Remission in ~67% at 6 months. Not durable — most need repeat injections; only ~67% of initial responders maintain remission at one year with repeated injections. Submucosal fibrosis from repeated injections complicates subsequent myotomy. Not a definitive therapy. Use in elderly/infirm patients who cannot tolerate definitive procedures.
• Pneumatic dilation (PD): 30–40 mm balloons tear LES muscle fibers. Good-to-excellent response in 60–85% after a single session. ~50% require additional therapy within 5 years. Perforation rate 2–5%. Reflux esophagitis in ~5%.
• Laparoscopic Heller myotomy (LHM): Surgical division of LES muscle under direct visualization. Always paired with partial fundoplication — Dor (anterior) or Toupet (posterior). Nissen (360°) fundoplication is avoided — the aperistaltic esophagus cannot push through a complete wrap. Good-to-excellent response 70–90%. 85% sustained remission at 10 years, 65% at 20 years. Reflux esophagitis ~10%.
• POEM (per-oral endoscopic myotomy): Submucosal tunnel approach, myotomy performed from inside. Meta-analysis of 2,373 patients: 98% short-term success. Advantage: proximal extension of myotomy for Type III. Disadvantage: no antireflux procedure — GERD symptoms 8.5%, reflux esophagitis 13%, abnormal pH monitoring in 47%. Blown-out myotomy (BOM) described in 30% of POEM patients at 5 years — associated with treatment failure.
• The landmark RCTs:

Boeckxstaens et al., NEJM 2011 Comparison: PD vs LHM (n=201, mean 43 months follow-up) Result: No significant difference. Success rates 86% PD vs 90% LHM at 2 years; 82% vs 84% at 5 years. Established PD and LHM as equivalent in safety and efficacy.

Ponds et al., JAMA 2019 Comparison: POEM vs PD (n=126, 2-year primary endpoint) Result: POEM superior — 92% vs 54% at 2 years; 81% vs 40% at 5 years. Reflux esophagitis: 41% POEM vs 7% PD. POEM wins on efficacy; pays a significant GERD price.

Werner et al., NEJM 2019 Comparison: POEM vs LHM + Dor fundoplication (n=221, 2-year primary endpoint) Result: Noninferiority met — 83% POEM vs 82% LHM. No significant differences in esophageal function or quality of life. Reflux esophagitis: 44% POEM vs 29% LHM at 2 years; 41% vs 31% at 5 years. POEM and LHM equivalent in efficacy; POEM carries higher reflux burden without fundoplication.

• Guideline recommendations:
  • ACG: LHM, PD, and POEM are all comparable for Type I and II. POEM preferred for Type III.
  • ASGE: Tailored myotomy (POEM or LHM) preferred for Type III. Patients should be counseled on POEM's higher GERD risk.

Board Pearls

Board trap: POEM versus LHM for Type I/II — equivalent efficacy, but POEM carries significantly higher GERD burden because there is no fundoplication.

High-yield: Nissen fundoplication is contraindicated in achalasia. Partial wrap (Dor or Toupet) is the rule when peristalsis is impaired.

High-yield: Botulinum toxin is not a definitive therapy. If a board option offers it as first-line — it is a distractor.

Motility 03: Achalasia — Pathophysiology, Etiology, and Diagnosis

Episode keywords: achalasia pathophysiology, ganglion cell degeneration, achalasia subtypes, achalasia diagnosis, pseudoachalasia, Chagas disease esophagus, bird beak sign, achalasia manometry, Type I Type II Type III achalasia

Episode Summary

Achalasia means "does not relax." The name is the disease. This episode builds from the tissue level — selective inhibitory neuron degeneration — through the HRM subtypes that predict treatment response, to the diagnostic pathway that catches malignancy before it is missed. Understanding the pathophysiology allows you to derive every clinical feature rather than memorize it.

Key Topics

• Core lesion: Degeneration of myenteric (Auerbach) plexus ganglion cells, with preferential loss of inhibitory (nitric oxide-producing) neurons. Cholinergic excitatory neurons are relatively spared, producing unopposed excitation — this is why basal LES pressure rises.
• Result: Aperistalsis in the esophageal body; incomplete LES relaxation due to lost inhibitory innervation. Neuronal damage can extend to the dorsal motor nucleus of the vagus and vagal fibers.
• Etiology: Autoimmune (HLA associations, viral triggers including HSV, measles, HPV); emerging Type 2 allergic inflammation hypothesis (eosinophil/mast cell accumulation with association to EoE).
• Chagas disease: Trypanosoma cruzi infection causes identical ganglion cell loss. Manometrically indistinguishable from primary achalasia. Mandatory serologies for patients from Central/South America.
• Pseudoachalasia: Malignancy at the EGJ (classically adenocarcinoma) can mimic achalasia by neural invasion or paraneoplastic mechanisms. Red flags: age >55, rapid progression (<1 year), significant weight loss, endoscopic resistance traversing the GEJ. EGD before treatment is mandatory.
• Diagnostic pathway: Chest X-ray (widened mediastinum, absent gastric bubble) → barium swallow (bird-beak sign, dilated or sigmoid esophagus) → endoscopy (retained material, LES traversable with gentle pressure) → HRM confirmation.
• The three subtypes:
  • Type I: Inert body, no pressurization. Complete loss of excitatory and inhibitory neural function.
  • Type II: Panesophageal pressurization ≥20% of swallows. Residual excitatory function. Best treatment response.
  • Type III: Premature (spastic) contractions ≥20% of swallows, DCI >450, DL <4.5 sec. Worst treatment response.

Board Pearls

High-yield: Type II → best response. Type III → worst response. This is the most consistently tested point about achalasia subtypes.

Board trap: The LES in achalasia traverses easily with gentle endoscopic pressure. If it does NOT pass — think pseudoachalasia, not achalasia.

High-yield: Absent gastric air bubble on chest X-ray in a dysphagia patient = elevated IRP preventing swallowed air from reaching the stomach.